home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Diamond Collection
/
The Diamond Collection (Software Vault)(Digital Impact).ISO
/
cdr16
/
med9505a.zip
/
M9550022.TXT
< prev
next >
Wrap
Text File
|
1995-03-04
|
2KB
|
32 lines
Document 0022
DOCN M9550022
TI Measles seroprevalence and vaccine response in HIV-infected adults.
DT 9505
AU Wallace MR; Hooper DG; Graves SJ; Malone JL; Department of Internal
Medicine (HIV Division), Naval Medical; Center, San Diego.
SO Vaccine. 1994 Oct;12(13):1222-4. Unique Identifier : AIDSLINE
MED/95141685
AB Measles in HIV-infected patients can be a severe, even fatal, illness.
The prevalence of measles seropositivity in HIV-infected adults and the
durability of these antibody levels are uncertain. A prospective survey
of 210 HIV-infected adults found that 95% of the adults had demonstrable
antibodies using a standard ELISA technique. Seropositivity was no
different in patients with CD4 counts over 400, from those with more
advanced disease and CD4 counts under 200 (p = 0.8). Six seronegative
patients were vaccinated and had serial antibody determinations: two of
six (33%) patients had a durable positive antibody response at 1 year,
and none had any observed toxicity. Vaccination of the identified
measles-seronegative HIV-infected adults who are at high risk for
measles is recommended, but a measurable antibody response may be
expected in only a minority of cases.
DE Adult Antibodies, Viral/*BLOOD AIDS-Related Opportunistic
Infections/COMPLICATIONS/IMMUNOLOGY/ PREVENTION & CONTROL Cohort
Studies Female Human HIV Infections/COMPLICATIONS/*IMMUNOLOGY Male
Measles/COMPLICATIONS/IMMUNOLOGY/PREVENTION & CONTROL Measles
Vaccine/IMMUNOLOGY/*PHARMACOLOGY Measles Virus/*IMMUNOLOGY Prospective
Studies CLINICAL TRIAL JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).